Licensing status

Publication and contact information



NGFI-A binding protein 2 (EGR1 binding protein 2;
NAB2); signal transducer and activator of transcription 6 (STAT6)

Two separate genetic sequencing studies identified a NAB2-STAT6 gene fusion associated with solitary fibrous tumors (SFTs), which could provide a new therapeutic target. In the first study, whole-exome sequencing of 53 SFT samples identified NAB2-STAT6 fusion transcripts in 29 of the samples. In a second study, whole-genome and whole-transcriptome sequencing of tumor and matched normal tissues from a patient with meningeal malignant SFT identified a NAB2-STAT6 fusion in the tumor tissue. The fusion also was found in all of the 51 other SFT samples tested. In benign prostate cells, lentiviral-mediated overexpression of the fusion protein increased cell proliferation compared with normal expression. Next steps for both groups include testing the effects of inhibiting STAT6 or downstream signaling targets.

SciBX 6(4); doi:10.1038/scibx.2013.83
Published online Jan. 31, 2013

Findings in first study unpatented; unavailable for licensing

Patent application filed for findings in second study; available for

Chmielecki, J. et al. Nat. Genet.; published online Jan. 13, 2013;
Contact: Matthew Meyerson, Harvard Medical School, Boston, Mass.

Robinson, D.R. et al. Nat. Genet.; published online Jan. 13, 2013;
Contact: Arul M. Chinnaiyan, University of Michigan Medical School, Ann Arbor, Mich.

Contact: Cristina R. Antonescu, Memorial Sloan-Kettering Cancer Center, New York, N.Y.